UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 


 

 

 

 

 

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

 

 


 

 

 

 

 

 

Filed by the Registrant     ☒ 

Filed by a Party other than the Registrant    ☐

 

 

 

 

Check the appropriate box:

 

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a‑12

 

 

 

UROGEN PHARMA LTD.


 

 

 

 

(Name of Registrant as Specified In Its Charter)

 

 


 

 

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

 

 

Payment of Filing Fee (Check all boxes that apply):

 

 

 

No fee required.

   

Fee paid previously with preliminary materials

   

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 


 

 

 

 

proxycardfinal08012023pg1of2.jpg
proxycardfinalpg2of2.jpg
 

UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more UroGen Pharma Charts.
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more UroGen Pharma Charts.